The U.S. Food and Drug Administration (FDA) approved Gazyva® to treat adults with lupus nephritis in October 2025. Gazyva targets and removes harmful B cells to help protect the kidneys in people with ...

MAJESTY, the first global Phase III study in primary membranous nephropathy, met its primary endpoint of complete remission at two years –– Up to 30% of people with membranous nephropathy progress to ...

Amgen’s bad luck in lupus may finally be coming to an end. Daxdilimab, a monoclonal antibody acquired from Horizon Therapeutics in 2023, hit the primary endpoint in a phase 2 trial for discoid lupus ...

Anyone who has dealt with a lingering cough knows how quickly it can take over daily life. It interrupts conversations, disrupts sleep and makes even simple things like eating or drinking ...

Please provide your email address to receive an email when new articles are posted on . FDA has granted breakthrough designation for litifilimab in patients with cutaneous lupus erythematosus. The ...

Archana Koirala has done research with funding from the Australian Department of Health, Disability and Ageing, and NSW health. She is the chair of the Vaccination Special Interest Group and a ...

UPDATE: Following Congress' passage, the President signed this legislation into law on Feb. 3, 2026. This afternoon, Congress took the final steps in the FY 2026 budget process, passing legislation ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Subcutaneous anifrolumab improved over placebo in BICLA ...

Most cancer patients hope their tumors disappear quickly, but a UK mom is actually “waiting” for hers to grow. “I am constantly waiting for the tumors to grow big enough to get treatment that is ...

My blood work showed that I was slightly low in vitamin D, so my doctor recommended that I take a supplement. My pharmacist ...